The Bronx Rising Initiative (BRI) has been working to protect Bronxites from COVID-19 since the onset of the pandemic. On April 12th, 2021 BRI announced the launch of our homebound COVID-19 vaccine program in partnership with VIP Community Services. Our homebound vaccine program initially utilized the Janssen Johnson & Johnson vaccines. On April 13th, 2021, the Janssen COVID-19 vaccine was paused by government health agencies after reports of a rare and severe type of blood clot in six individuals following administration. However, the Bronx Rising Initiative homebound vaccine program was able to continue by instead providing these homebound Bronxites with the Moderna COVID-19 vaccine.
Now federal health agencies can confirm that a total of 15 cases of TTS have been reported, including the original six reported cases. These 15 instances were out of the more than 6.8 million Janssen Johnson & Johnson vaccines that had previously been administered. All of these cases occurred in women between the ages of 18 and 59, with a median age of 37 years.
On April 23rd, 2021 the Bronx Rising Initiative was pleased to learn that following a thorough safety review, including two meetings of the CDC’s Advisory Committee on Immunization Practices, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention, it was determined that the recommended pause regarding the use of the Janssen Johnson & Johnson COVID-19 vaccine in the U.S. should be lifted, and use of the vaccine should resume. With this recommendation, The Bronx Rising Initiative with VIP Community Services will resume the use of the Janssen Johnson & Johnson COVID-19 Vaccine for our homebound program.
Safety remains our top priority. The dangers of contracting COVID-19 still exist, and we encourage any Bronxites that are unable to receive their vaccine at a designated vaccination site to sign-up for our free homebound program at www.bronxrisinginitiative.com.
We rise together!"
Managing Director, Bronx Rising Initiative